Clinical Trial Update: Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of YM178 (mirabegron) for overactive bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Mirabegron (mirabegron)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Urinary Bladder, Overactive | Phase 2 | Status: COMPLETED